Disposition kinetics of two oral forms of quinidine

W. A. Mahon, Michael Mayersohn, T. Inaba

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

There are relatively few studies on the disposition properties of quinidine. We have studied in 10 normal subjects conventional quinidine sulfate and a slow-release quinidine bisulfate. Single and repetitive doses were given; blood and urine concentrations were measured by the method of Cramer and Isaakson.5 After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 ± 0.22 μg/ml (±SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 ± 0.12 μg/ml T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate. One fourth of both forms of the drug was recovered in the urine. Total body clearance was 0.36 Llkg ·hr and renal clearance was 117 ± 22 ml/min for both. With multiple dosing the serum quinidine concentration was higher than these predicted from the results of the single-dose study. Based on the mean estimates of quinidine half-life of 6 hr, a rapid method for achieving steady-state levels of quinidine would be to give an initial dose twice that of the maintenance dose. With the slow-release product if an equivalent dose was given every 12 hr, the mean steady-state quinidine serum concentration would be approximately the same.

Original languageEnglish (US)
Pages (from-to)566-575
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume19
Issue number5 PART 1
StatePublished - May 1976
Externally publishedYes

Fingerprint

Quinidine
Tablets
Urine
Serum
Half-Life
Kidney

ASJC Scopus subject areas

  • Pharmacology

Cite this

Disposition kinetics of two oral forms of quinidine. / Mahon, W. A.; Mayersohn, Michael; Inaba, T.

In: Clinical Pharmacology and Therapeutics, Vol. 19, No. 5 PART 1, 05.1976, p. 566-575.

Research output: Contribution to journalArticle

Mahon, W. A. ; Mayersohn, Michael ; Inaba, T. / Disposition kinetics of two oral forms of quinidine. In: Clinical Pharmacology and Therapeutics. 1976 ; Vol. 19, No. 5 PART 1. pp. 566-575.
@article{3102a5d9aef843509359f753891a4523,
title = "Disposition kinetics of two oral forms of quinidine",
abstract = "There are relatively few studies on the disposition properties of quinidine. We have studied in 10 normal subjects conventional quinidine sulfate and a slow-release quinidine bisulfate. Single and repetitive doses were given; blood and urine concentrations were measured by the method of Cramer and Isaakson.5 After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 ± 0.22 μg/ml (±SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 ± 0.12 μg/ml T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate. One fourth of both forms of the drug was recovered in the urine. Total body clearance was 0.36 Llkg ·hr and renal clearance was 117 ± 22 ml/min for both. With multiple dosing the serum quinidine concentration was higher than these predicted from the results of the single-dose study. Based on the mean estimates of quinidine half-life of 6 hr, a rapid method for achieving steady-state levels of quinidine would be to give an initial dose twice that of the maintenance dose. With the slow-release product if an equivalent dose was given every 12 hr, the mean steady-state quinidine serum concentration would be approximately the same.",
author = "Mahon, {W. A.} and Michael Mayersohn and T. Inaba",
year = "1976",
month = "5",
language = "English (US)",
volume = "19",
pages = "566--575",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5 PART 1",

}

TY - JOUR

T1 - Disposition kinetics of two oral forms of quinidine

AU - Mahon, W. A.

AU - Mayersohn, Michael

AU - Inaba, T.

PY - 1976/5

Y1 - 1976/5

N2 - There are relatively few studies on the disposition properties of quinidine. We have studied in 10 normal subjects conventional quinidine sulfate and a slow-release quinidine bisulfate. Single and repetitive doses were given; blood and urine concentrations were measured by the method of Cramer and Isaakson.5 After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 ± 0.22 μg/ml (±SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 ± 0.12 μg/ml T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate. One fourth of both forms of the drug was recovered in the urine. Total body clearance was 0.36 Llkg ·hr and renal clearance was 117 ± 22 ml/min for both. With multiple dosing the serum quinidine concentration was higher than these predicted from the results of the single-dose study. Based on the mean estimates of quinidine half-life of 6 hr, a rapid method for achieving steady-state levels of quinidine would be to give an initial dose twice that of the maintenance dose. With the slow-release product if an equivalent dose was given every 12 hr, the mean steady-state quinidine serum concentration would be approximately the same.

AB - There are relatively few studies on the disposition properties of quinidine. We have studied in 10 normal subjects conventional quinidine sulfate and a slow-release quinidine bisulfate. Single and repetitive doses were given; blood and urine concentrations were measured by the method of Cramer and Isaakson.5 After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 ± 0.22 μg/ml (±SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 ± 0.12 μg/ml T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate. One fourth of both forms of the drug was recovered in the urine. Total body clearance was 0.36 Llkg ·hr and renal clearance was 117 ± 22 ml/min for both. With multiple dosing the serum quinidine concentration was higher than these predicted from the results of the single-dose study. Based on the mean estimates of quinidine half-life of 6 hr, a rapid method for achieving steady-state levels of quinidine would be to give an initial dose twice that of the maintenance dose. With the slow-release product if an equivalent dose was given every 12 hr, the mean steady-state quinidine serum concentration would be approximately the same.

UR - http://www.scopus.com/inward/record.url?scp=0017080173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017080173&partnerID=8YFLogxK

M3 - Article

C2 - 1277713

AN - SCOPUS:0017080173

VL - 19

SP - 566

EP - 575

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5 PART 1

ER -